Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Pfizer

Status and phase: Active, not recruiting; Phase 2

Conditions: Lyme Borreliosis

Treatments: Biological: VLA15; Biological: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04801420

C4601008 (Other Identifier)

VLA15-221

Details and patient eligibility

About

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.

Full description

VLA15-221 is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study, which is set up in two parts: Main Study Phase (Part A) and Booster Phase (Part B). In Part A 600 subjects aged 5-65 years will be enrolled 1:1:1 into three groups: Group 1 will be vaccinated with VLA15 at Month 0-2-6, Group 2 will be vaccinated with VLA15 at Month 0-6 and with placebo at Month 2 and Group 3 will be vaccinated with placebo at Month 0-2-6. In Part B all eligible subjects will receive booster injections with VLA15 or placebo at Month 18, 30 and 42.

Enrollment: 625 patients

Sex: All

Ages: 5 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject is aged 5 to 65 years at the day of screening (Visit 0)

• Subject is of good general health

• Parent(s)/legal representative(s) and subject understand the study and its procedures, agree to its provisions

  • for subjects aged 18-65 years: written informed consent prior to any study related procedures
  • for subjects aged 5-17 years: written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable, prior to any study related procedures.

• If subject is of childbearing potential: Subject has a negative serum pregnancy test at screening (Visit 0) and agrees to employ adequate birth control measures according to following timelines:

  • Main Study Phase: duration of entire study
  • Booster Phase: until 5 months after each booster vaccination (Booster 1 until Month 23, Booster 2 until Month 35 and Booster 3 until Month 47)

• Subject is willing and able to comply with scheduled visits, treatment plan, and other study procedures

• Subject is available for the duration of the study and can be contacted by telephone during study participation

Exclusion criteria

• Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB, or received treatment for LB within the last 3 months prior to Day 1;
• Subject received previous vaccination against LB;
• Subject had a tick bite within 4 weeks prior to Day 1;
• Subject has a medical history of or currently has a clinically relevant disease;
• Subject has a medical history of or currently has a neuro- inflammatory or autoimmune disease;
• Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the 3 weeks prior to Day 1;
• Subject has received an active or passive immunization within 4 weeks prior to Day 1;
• Subject has received any other registered or non-registered medicinal product in another clinical trial within 4 weeks prior to vaccination at Day 1;
• Subject has a known or suspected defect of the immune system or received immuno-suppressive therapy within 4 weeks prior to Day 1;
• Subject has a history of anaphylaxis of unknown cause or severe allergic reactions of unknown cause or has a known hypersensitivity or allergic reactions to one of the components of the vaccine;
• Subject had any malignancy in the past 5 years;
• Subject is pregnant, has plans to become pregnant during the course of the study or is lactating at the time of enrollment;
• Subject has donated or plans to donate blood or blood-derived products 4 weeks prior to Day 1;
• Subject has any condition that may compromise its well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
• Subject is in a dependent relationship with the sponsor/investigator

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

625 participants in 3 patient groups, including a placebo group

Part A+B - Group 1

Experimental group

Description:

Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18, 30 and 42

Treatment:

Biological: VLA15

Part A+B - Group 2

Experimental group

Description:

Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18, 30 and 42

Treatment:

Biological: Placebo

Biological: VLA15

Part A+B - Group 3

Placebo Comparator group

Description:

Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18, 30 and 42

Treatment:

Biological: Placebo